Last reviewed · How we verify
Topiramate 100mg
Topiramate 100mg, marketed by the University of Minnesota, is a well-established drug in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing market presence and established efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Topiramate 100mg |
|---|---|
| Also known as | Topamax |
| Sponsor | University of Minnesota |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (PHASE3)
- Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds (PHASE2)
- A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate (PHASE1)
- Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD (PHASE2)
- A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy (PHASE4)
- Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (PHASE2)
- Valproate Versus Topiramate in Migraine (PHASE3)
- The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |